Alvotech Appoints Sarah Tanksley as Chief Quality Officer

REYKJAVIK, Iceland, Oct. 11, 2022 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a worldwide biotech firm specializing within the improvement and manufacture of biosimilar medicines for sufferers worldwide, right now introduced that Sarah Tanksley will be part of its company management group as Chief Quality Officer, efficient October 14. Ms. Tanksley succeeds Reem Malki, who’s stepping down for private causes.

“Sarah has been actively working with Alvotech as a consultant and we are very pleased that she will join our team in this new capacity,” stated Mark Levick, Chief Executive Officer of Alvotech. “Her familiarity with our operation facilitates a smooth transition and we are excited to benefit further from her experience in regulatory compliance and GMP. Sarah brings strong capabilities to the role of Chief Quality Officer, having excelled in regulatory agency roles as well as a respected industry practitioner. I also want to thank Reem for her vital contribution to the Alvotech team, as we built a world-class biosimilars development and manufacturing platform and achieved successful market launches of our first biosimilar in both Europe and Canada.”

Ms. Tanksley has 20 years of expertise inside the U.S. National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), and as an trade marketing consultant. She teaches graduate programs in GMP compliance and Regulatory Affairs as an Adjunct Professor within the Graduate Biochemistry and Molecular Biology Program at Georgetown University School of Medicine and with the Advanced Academic Program at Johns Hopkins University. Sarah has an MS diploma in Bioscience Regulatory Affairs from Johns Hopkins University, as effectively as an MS diploma in Biochemistry and Molecular Biology from Georgetown University School of Medicine.

About Alvotech

Alvotech is a biotech firm, based by Robert Wessman, targeted solely on the event and manufacture of biosimilar medicines for sufferers worldwide. Alvotech seeks to be a worldwide chief within the biosimilar house by delivering prime quality, cost-effective merchandise, and companies, enabled by a totally built-in strategy and broad in-house capabilities. Alvotech’s present pipeline incorporates eight biosimilar candidates aimed toward treating autoimmune problems, eye problems, osteoporosis, respiratory illness, and most cancers. Alvotech has shaped a community of strategic business partnerships to supply international attain and leverage native experience in markets that embody the United States, Europe, Japan, China, and different Asian international locations and huge components of South America, Africa and the Middle East. Alvotech’s business companions embody Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each business partnership covers a novel set of product(s) and territories. Except as particularly set forth therein, Alvotech disclaims duty for the content material of periodic filings, disclosures and different experiences made accessible by its companions. For extra info, please go to www.alvotech.com. None of the knowledge on the Alvotech web site shall be deemed a part of this press launch.

Forward-Looking Statements

This press launch incorporates forward-looking statements as that time period is outlined within the Private Securities Litigation Reform Act of 1995, together with with respect to the Alvotech’s partnerships, pipeline and regulatory approvals, and the transition of Ms. Tanksley into her function as Chief Quality Officer. Any assertion describing Alvotech’s objectives, expectations, monetary or different projections, intentions or beliefs, or administration adjustments is a forward-looking assertion and ought to be thought-about an at-risk assertion. Such statements are topic to quite a lot of dangers, uncertainties and assumptions, together with these associated to the affect that the COVID-19 pandemic might have on Alvotech’s business, and together with the scope, progress and growth of Alvotech’s medical trials and ramifications for the price thereof; medical, scientific, regulatory and technical developments; administration adjustments and people inherent within the strategy of growing and commercializing product candidates which are secure and efficient, and within the endeavor of constructing a business round such product candidates. In mild of those dangers and uncertainties, and different dangers and uncertainties which are described within the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in paperwork that Alvotech could sometimes file or furnish with the SEC, the occasions and circumstances mentioned in such forward-looking statements could not happen, and Alvotech’s precise outcomes might differ materially and adversely from these anticipated or implied thereby. Although Alvotech’s forward-looking statements mirror the nice religion judgment of its administration, these statements are primarily based solely on details and elements at the moment identified by Alvotech. As a end result, you’re cautioned to not depend on these forward-looking statements.

CONTACTS

Alvotech Investor Relations and Global Communication
Benedikt Stefansson
alvotech.ir[at]alvotech.com